Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Rocky Lee Baker

TitleAssoc Professor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-IMM MICRO GENERAL OPER
Phone303/724-8410

    Collapse Research 
    Collapse research activities and funding
    R01AI146202     (BAKER, ROCKY LEE)Jun 2, 2020 - May 31, 2025
    NIH
    Responses to Hybrid Insulin Peptides as Biomarkers of Disease Activity in Human Type 1 Diabetes
    Role: Principal Investigator

    R21AI133059     (BAKER, ROCKY LEE)Jan 1, 2018 - Dec 31, 2020
    NIH
    T cells reactive to Hybrid Insulin Peptides (HIPs) as biomarkers in autoimmune diabetes
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Crawford SA, Wiles TA, Wenzlau JM, Powell RL, Barbour G, Dang M, Groegler J, Barra JM, Burnette KS, Hohenstein AC, Baker RL, Tse HM, Haskins K, Delong T. Cathepsin D Drives the Formation of Hybrid Insulin Peptides Relevant to the Pathogenesis of Type 1 Diabetes. Diabetes. 2022 12 01; 71(12):2793-2803. PMID: 36041196.
      View in: PubMed
    2. Wenzlau JM, DiLisio JE, Barbour G, Dang M, Hohenstein AC, Nakayama M, Delong T, Baker RL, Haskins K. Insulin B-chain hybrid peptides are agonists for T cells reactive to insulin B:9-23 in autoimmune diabetes. Front Immunol. 2022; 13:926650. PMID: 36032090.
      View in: PubMed
    3. Jamison BL, DiLisio JE, Beard KS, Neef T, Bradley B, Goodman J, Gill RG, Miller SD, Baker RL, Haskins K. Tolerogenic Delivery of a Hybrid Insulin Peptide Markedly Prolongs Islet Graft Survival in the NOD Mouse. Diabetes. 2022 03 01; 71(3):483-496. PMID: 35007324.
      View in: PubMed
    4. Srivastava N, Hu H, Vomund AN, Peterson OJ, Baker RL, Haskins K, Teyton L, Wan X, Unanue ER. Chromogranin A Deficiency Confers Protection From Autoimmune Diabetes via Multiple Mechanisms. Diabetes. 2021 12; 70(12):2860-2870. PMID: 34497137.
      View in: PubMed
    5. Wiles TA, Hohenstein A, Landry LG, Dang M, Powell R, Guyer P, James EA, Nakayama M, Haskins K, Delong T, Baker RL. Characterization of Human CD4 T Cells Specific for a C-Peptide/C-Peptide Hybrid Insulin Peptide. Front Immunol. 2021; 12:668680. PMID: 34113344.
      View in: PubMed
    6. Firdessa-Fite R, Johnson SN, Leon MA, Khosravi-Maharlooei M, Baker RL, Sestak JO, Berkland C, Creusot RJ. Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes. Diabetes. 2021 06; 70(6):1334-1346. PMID: 33468513.
      View in: PubMed
    7. Arribas-Layton D, Guyer P, Delong T, Dang M, Chow IT, Speake C, Greenbaum CJ, Kwok WW, Baker RL, Haskins K, James EA. Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01. Diabetes. 2020 07; 69(7):1492-1502. PMID: 32291282.
      View in: PubMed
    8. Baker RL, Jamison BL, Haskins K. Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2019 08; 26(4):195-200. PMID: 31166225.
      View in: PubMed
    9. Baker RL, Rihanek M, Hohenstein AC, Nakayama M, Michels A, Gottlieb PA, Haskins K, Delong T. Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1830-1840. PMID: 31175101.
      View in: PubMed
    10. Jamison BL, Neef T, Goodspeed A, Bradley B, Baker RL, Miller SD, Haskins K. Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells. J Immunol. 2019 07 01; 203(1):48-57. PMID: 31109955.
      View in: PubMed
    11. Dirice E, Kahraman S, De Jesus DF, El Ouaamari A, Basile G, Baker RL, Yigit B, Piehowski PD, Kim MJ, Dwyer AJ, Ng RWS, Schuster C, Vethe H, Martinov T, Ishikawa Y, Teo AKK, Smith RD, Hu J, Haskins K, Serwold T, Qian WJ, Fife BT, Kissler S, Kulkarni RN. Increased ?-cell proliferation before immune cell invasion prevents progression of type 1 diabetes. Nat Metab. 2019 05; 1(5):509-518. PMID: 31423480.
      View in: PubMed
    12. Baker RL, Jamison BL, Wiles TA, Lindsay RS, Barbour G, Bradley B, Delong T, Friedman RS, Nakayama M, Haskins K. CD4 T Cells Reactive to Hybrid Insulin Peptides Are Indicators of Disease Activity in the NOD Mouse. Diabetes. 2018 09; 67(9):1836-1846. PMID: 29976617.
      View in: PubMed
    13. Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, Reisdorph N, Haskins K. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun. 2017 03; 78:11-18. PMID: 27802879.
      View in: PubMed
    14. Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, Armstrong M, Powell RL, Reisdorph N, Kumar N, Elso CM, DeNicola M, Bottino R, Powers AC, Harlan DM, Kent SC, Mannering SI, Haskins K. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016 Feb 12; 351(6274):711-4. PMID: 26912858.
      View in: PubMed
    15. Baker RL, Bradley B, Wiles TA, Lindsay RS, Barbour G, Delong T, Friedman RS, Haskins K. Cutting Edge: Nonobese Diabetic Mice Deficient in Chromogranin A Are Protected from Autoimmune Diabetes. J Immunol. 2016 Jan 01; 196(1):39-43. PMID: 26608914.
      View in: PubMed
    16. Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, Rewers MR, Michels A, Haskins K. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun. 2014 May; 50:38-41. PMID: 24239002.
      View in: PubMed
    17. Baker RL, Delong T, Barbour G, Bradley B, Nakayama M, Haskins K. Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice. J Immunol. 2013 Oct 15; 191(8):3990-4. PMID: 24043895.
      View in: PubMed
    18. Delong T, Baker RL, He J, Haskins K. Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunol Res. 2013 Mar; 55(1-3):167-72. PMID: 22971988.
      View in: PubMed
    19. Delong T, Baker RL, He J, Barbour G, Bradley B, Haskins K. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes. 2012 Dec; 61(12):3239-46. PMID: 22912420.
      View in: PubMed
    20. Baker RL, Mallevaey T, Gapin L, Haskins K. T cells interact with T cells via CD40-CD154 to promote autoimmunity in type 1 diabetes. Eur J Immunol. 2012 Mar; 42(3):672-80. PMID: 22488364.
      View in: PubMed
    21. Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Barbour G, Bradley B, Haskins K. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes. 2011 Sep; 60(9):2325-30. PMID: 21734016.
      View in: PubMed
    22. Baker RL, Wagner DH, Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun. 2008 Dec; 31(4):385-92. PMID: 18951762.
      View in: PubMed
    Baker's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)